RxDoctor Payments Data

Bryan Beck, MD

Critical Care Medicine · Springfield, MONPI 1760986467

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $897 of the $997 with a category attached, or 90.0%. It is spread thinly across 19 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $502, 4.0 times the $125 reported in 2021.

$997in general payments, 2019–2025

Across 31 payments — averaging $32.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$162
  • Sanofi$158
  • Sanofi-aventis U.S. LLC$100
  • AstraZeneca$71
  • Insmed, Inc.$70
  • Genentech USA, Inc.$55
  • plus $380 from 13 others

What the payments were for

  • Food & beverage$89790%
  • Education$10010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$997 in reported general payments places this provider in the 80th percentile of 208 critical care medicine providers in Missouri.

See all critical care medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$13,820
Medicare patients
54
Services billed
100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban14$15,509
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$13,664
BreynaBudesonide/Formoterol Fumarate12$1,566
Albuterol Sulfate HfaAlbuterol Sulfate17$512
Fluticasone Propionate14$244
Prednisone13$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$24$13,66417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 208 critical care medicine providers in Missouri.

Other critical care medicine in Springfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →